Therapeutic drug monitoring of 5-fluorouracil James J. LeeJan H. BeumerEdward Chu Review Article 23 May 2016 Pages: 447 - 464
Pharmacokinetic variations in cancer patients with liver dysfunction: applications and challenges of pharmacometabolomics Ali Aboel DahabDhia El-HagNorman W. Smith Review Article 09 April 2016 Pages: 465 - 489
Phase 1 study to evaluate the effect of the MEK inhibitor trametinib on cardiac repolarization in patients with solid tumours Amita PatnaikAnthony TolcherSunil Sharma Original Article 08 July 2016 Pages: 491 - 500
A multicenter phase II trial of S-1 combined with bevacizumab after platinum-based chemotherapy in patients with advanced non-squamous non-small cell lung cancer Kazuhiko YamadaMasao IchikiTomoaki Hoshino Original Article 11 July 2016 Pages: 501 - 507
Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients Ankit MadanBenjamin S. JonesFrancisco Robert Original Article 14 July 2016 Pages: 509 - 515
Effects of a bolus injection of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in rats receiving continuous infusion of 5-fluorouracil Shinji KobuchiAsuka HayashiToshiyuki Sakaeda Original Article 14 July 2016 Pages: 517 - 523
Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours Kan YonemoriKenji TamuraYasuo Takahashi Original Article Open access 15 July 2016 Pages: 525 - 531
SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia Jeong-Hyun KimChansu LeeSung-Soo Yoon Original Article 15 July 2016 Pages: 533 - 540
A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer D. J. RenoufD. HedleyM. J. Moore Original Article 15 July 2016 Pages: 541 - 545
Ethnic sensitivity assessment of the antibody–drug conjugate trastuzumab emtansine (T-DM1) in patients with HER2-positive locally advanced or metastatic breast cancer Chunze LiBei WangSandhya Girish Original Article 16 July 2016 Pages: 547 - 558
Occurrence of hepatotoxicity with pazopanib and other anti-VEGF treatments for renal cell carcinoma: an observational study utilizing a distributed database network Sumitra ShantakumarBeth L. NordstromJeanenne Nelson Original Article Open access 20 July 2016 Pages: 559 - 566
A phase I study of the combination of panitumumab and bevacizumab in KRAS wild-type colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin, irinotecan and bevacizumab Naoki TakahashiSatoru IwasaYasuhide Yamada Original Article 20 July 2016 Pages: 567 - 575
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer Muhammad S. BegNilofer S. AzadMichael A. Morse Original Article 23 July 2016 Pages: 577 - 584
Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study) Takao TakahashiYasunori EmiKyushu Study Group of Clinical Cancer (KSCC) Original Article 28 July 2016 Pages: 585 - 593
Protein expression of ATP-binding cassette transporters ABCC10 and ABCC11 associates with survival of colorectal cancer patients V. KrizkovaM. DubovaP. Soucek Original Article 28 July 2016 Pages: 595 - 603
Model-based prediction of progression-free survival in patients with first-line renal cell carcinoma using week 8 tumor size change from baseline Laurent ClaretJenny ZhengRene Bruno Original Article 28 July 2016 Pages: 605 - 610
The molecular mechanism of action of superactive human leptin antagonist (SHLA) and quadruple leptin mutein Lan-2 on human ovarian epithelial cell lines Elżbieta FiedorEwa Łucja Gregoraszczuk Original Article Open access 01 August 2016 Pages: 611 - 622
BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen Jung-woo ChaeYi Ling TeoAlexandre Chan Original Article 02 August 2016 Pages: 623 - 632
Myelosuppression by chemotherapy in obese patients with gynecological cancers Kensuke KamimuraYoshifumi MatsumotoYasuo Saijo Original Article 02 August 2016 Pages: 633 - 641
SM-1, a novel PAC-1 derivative, activates procaspase-3 and causes cancer cell apoptosis Yanfen ChenMeng SunQubo Zhu Original Article 03 August 2016 Pages: 643 - 654
Repression of phosphoglycerate dehydrogenase sensitizes triple-negative breast cancer to doxorubicin Xia ZhangWeijun Bai Short Communication 29 July 2016 Pages: 655 - 659